Inventory

12 Months Ended

Dec. 31, 2021

Inventory Disclosure [Abstract]

Inventory

(4)Inventory

The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventories as of December 31, 2021 and 2020 consist of the following:

In thousands	December 31, 2021		December 31, 2020
Raw materials	$	107,695	$	50,657
Work in process		41,965		30,388
Finished goods		206,270		107,819
Inventory	$	355,930	$	188,864

As of December 31, 2021 and 2020, we had $121.3 million and nil of Long-term inventory, respectively, as consumption is expected beyond our normal operating cycle.